Artal Group S.A. Immunic, Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.13 - $10.8 $649,425 - $6.21 Million	574,713 Added 82.1%	1,274,713 $1.79 Million
Q4 2020 Feb 11, 2021	SELL	$14.8 - $20.37 $1.48 Million - $2.04 Million	-100,000 Reduced 12.5%	700,000 $10.7 Million
Q3 2020 Nov 13, 2020	BUY	$11.74 - $22.0 $2.35 Million - $4.4 Million	200,000 Added 33.33%	800,000 $14.9 Million
Q2 2020 Aug 14, 2020	SELL	$5.67 - $15.86 $170,207 - $476,101	-30,019 Reduced 4.76%	600,000 $7.27 Million
Q4 2019 Feb 13, 2020	BUY	$6.4 - $10.23 $4.03 Million - $6.45 Million	630,019 New	630,019 $6.11 Million

56.2M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $30.6M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.